Skip to main content
Top
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

LPS promotes epithelial–mesenchymal transition and activation of TLR4/JNK signaling

Authors: Hangyu Li, Yan Li, Dan Liu, Jingang Liu

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

The endotoxin level in the portal and peripheral veins of hepatocellular carcinoma (HCC) patients is higher and lipopolysaccharide (LPS), has been reported to inhibit tumor growth. However, in this study, we found that LPS-induced Toll-like receptor 4 (TLR4) signaling was involved in tumor invasion and the molecular mechanism was investigated. The HCC cells were used to study the invasion ability of LPS-induced HCC cells and the epithelial–mesenchymal transition (EMT) in vitro. The in vitro experiments demonstrated that LPS could significantly enhance the invasive potential and induce EMT in HCC cells with TLR4 dependent. Further studies showed that LPS could directly activate JNK/MAPK signaling through TLR4 in HCC cells. Interestingly, blocking JNK/MAPK signaling significantly inhibited EMT occurrence. Our results indicate that TLR4/JNK/MAPK signaling is required for LPS-induced EMT, tumor cell invasion and metastasis, which provide molecular insights for LPS-related pathogenesis and a basis for developing new strategies against metastasis in HCC.
Literature
1.
2.
go back to reference Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21:59–69.CrossRefPubMed Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21:59–69.CrossRefPubMed
3.
go back to reference Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clin Cancer Res. 2006;12:5369–76.CrossRefPubMed Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clin Cancer Res. 2006;12:5369–76.CrossRefPubMed
4.
go back to reference Gao Q, Zhao YJ, Wang XY, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72:3546–56.CrossRefPubMed Gao Q, Zhao YJ, Wang XY, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72:3546–56.CrossRefPubMed
5.
6.
go back to reference Krishnan J, Selvarajoo K, Tsuchiya M, et al. Toll-like receptor signal transduction. Exp Mol Med. 2007;39(4):421–38.CrossRefPubMed Krishnan J, Selvarajoo K, Tsuchiya M, et al. Toll-like receptor signal transduction. Exp Mol Med. 2007;39(4):421–38.CrossRefPubMed
7.
go back to reference Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Pathol Res Int. 2012;172894. Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Pathol Res Int. 2012;172894.
8.
go back to reference Oyanagi J, Ogawa T, Sato H, et al. Epithelial–mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS One. 2012;7:e53209.PubMedCentralCrossRefPubMed Oyanagi J, Ogawa T, Sato H, et al. Epithelial–mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS One. 2012;7:e53209.PubMedCentralCrossRefPubMed
9.
go back to reference Araki K, Shimura T, Suzuki H, et al. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.PubMedCentralCrossRefPubMed Araki K, Shimura T, Suzuki H, et al. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.PubMedCentralCrossRefPubMed
10.
go back to reference Shuman Moss LA, Jensen-Taubman S, et al. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol. 2012;181:1895–9.PubMedCentralCrossRefPubMed Shuman Moss LA, Jensen-Taubman S, et al. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol. 2012;181:1895–9.PubMedCentralCrossRefPubMed
11.
go back to reference Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
12.
go back to reference Jung JW, Hwang SY, Hwang JS, et al. Ionising radiation induces changes associated with epithelial–mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer. 2007;43:1214–24.CrossRefPubMed Jung JW, Hwang SY, Hwang JS, et al. Ionising radiation induces changes associated with epithelial–mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer. 2007;43:1214–24.CrossRefPubMed
13.
go back to reference Lawrence MC, Jivan A, Shao C, Duan L, et al. The roles of MAPKs in disease. Cell Res. 2008;18(4):436–42.CrossRefPubMed Lawrence MC, Jivan A, Shao C, Duan L, et al. The roles of MAPKs in disease. Cell Res. 2008;18(4):436–42.CrossRefPubMed
Metadata
Title
LPS promotes epithelial–mesenchymal transition and activation of TLR4/JNK signaling
Authors
Hangyu Li
Yan Li
Dan Liu
Jingang Liu
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2347-5

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine